Alzheimer's drug not on European market for now
Europe's Medicine Agency in Amsterdam has decided not to allow the potential Alzheimer's medication Lecanemab on the European market, citing potential risks outweighing potential benefits, despite the drug being approved in other countries and showing promise in treating early-stage Alzheimer's patients.